Pulmonary Disease, Chronic ObstructivePhase 1NCT01267006
Blood Levels and Effects of GSK1325756 in Healthy Adult Volunteers Aged 40 to 80 Years Old
A Phase 1 study testing GSK1325756 in people with Pulmonary Disease, Chronic Obstructive, run by GlaxoSmithKline at 1 site in United Kingdom.
Trial summary
This study will invite two groups of volunteers to participate. The data from one group of volunteers will be used to find out how much study drug, known as GSK1325756, is in the blood after taking the drug twice in one day. Read more about this study
- Who is it for?
- Ages 40 to 85 yearsHealthy volunteers can take part
- Conditions the study is for
- Pulmonary Disease, Chronic Obstructive
- What is being tested?
- GSK1325756
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 5 Nov 2010to 27 Jan 2011
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 85 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Male or non-childbearing potential female who, at the at the time of signing the informed consent, aged between 40 and 64 years (inclusive) for enrolment in Part A - Cohort 1; between 65 and 80 years (inclusive) for enrolment in Part B - Cohort 2. A female of non-childbearing potential is defined as a pre-menopausal female with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<147 pmol/L) is confirmatory].
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures and objectives.
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase and bilirubin less than or equal to 1.5x Upper Limit of Normal (ULN) (isolated bilirubin greater than 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin less than 35%).
- Resting blood pressure (BP) of less than or equal to 140/90, irrespective of anti-hypertensive medication status for the subject.
- Body weight greater or equal to 60 kg for men and greater or equal to 45 kg for women; and Body Mass Index (BMI) within the range 19 to 32 kilograms per metres squared (kg/m2) (inclusive).
- Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until one week post last dose.
- Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
Who cannot join
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- A neutrophil count at screening of less than 2 x 10*9L. Repeat testing is not permitted.
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- A positive pre-study drug/alcohol screen, with the exception of a positive result considered by the investigator to be directly attributable to prescription medication approved for subject use during the study.
- A positive test for HIV antibody.
- History of regular alcohol consumption within 6 months of the study defined as an average weekly intake of greater than 21 units for males or greater than 14 units for females. One unit is equivalent to 8 g of alcohol: a half-pint (~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits.
Show all 21Show fewer
- Positive serum or urine human chorionic gonadotropin (hCG) test at screening or prior to first dose.
- Screening QT duration corrected for heart rate by Bazett's formula (QTcB) or QT correction for heart rate by Fridericia's formula (QTcF) greater than 450 msec; PR interval outside the range 120 to 200 msec or an ECG that it not suitable for QT measurements (e.g. poorly defined termination of T-wave).
- The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 3-months, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
- Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety, such as a subject who is taking a stable dose of anti-hypertensive medication for at least 3 months prior to the screening visit; or lipid lowering medications (statins or fibrates) for at least 3 months prior to the screening visit.
- Treatment with intravenous or intra-articular corticosteroids within 6 weeks of first dose of study medication.
- Current treatment with proton pump inhibitors (e.g. omeprazole, lansoprazole).
- Current treatment with H2-receptor antagonists (e.g. ranitidine or cimetidine).
- History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
- Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 3-month period.
- Unwillingness or inability to follow the procedures outlined in the protocol.
- Subject is mentally or legally incapacitated.
- Urinary cotinine or exhaled breath carbon monoxide (CO) levels indicative of smoking or history or regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
- Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior to the first dose of study medication.
- Direct involvement in the conduct of the study, or relative or any person directly involved in the conduct of the study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized Cross-over Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Twice Daily Oral Administration of GSK1325756, Compared to Placebo, in Healthy Subjects; and the Pharmacokinetic Profile of Twice Daily Oral Administration of GSK1325756 in Healthy Fed and Fasted Elderly Subjects
This study will invite two groups of volunteers to participate.
The data from one group of volunteers will be used to find out how much study drug, known as GSK1325756, is in the blood after taking the drug twice in one day. Data will also collected to find out if the level of cetain blood cells, known as neutrophils, change significantly after taking the study drug twice in one day. This group of volunteers will be aged 40 to 64 years of age.
The data from the other group of volunteers will be used to find out if taking the study drug, GSK1325756, twice in one day with or without food, makes a difference to the level of study drug in the blood. This group of volunteers will also provide data to find out if any study drug metabolites are present in the bile, a fluid secreted by the liver. This group of volunteers will be aged 65 to 80 years of age.
Read the detailed description
The current study will be conducted in two parts. In Part A - Cohort 1, healthy fed subjects aged 40 to 64 years (inclusive) will be enrolled to evaluate both the pharmacokinetics and pharmacodynamics of twice daily oral administration of GSK1325756 compared to matching placebo. In Part B - Cohort 2, healthy elderly subjects aged 65 to 80 years (inclusive) will be enrolled to evaluate the pharmacokinetic profile of twice daily oral administration of GSK1325756 for administered under fed and fasted conditions. Parts A and B may be performed in parallel.
The approximate duration of the current study is expected to be between 64 and 74 days. The study will require subjects to complete a screening visit within 30 days, followed by Part A - Cohort 1 enrolment requiring 3 x (3 day treatment period + 7 day washout period) or Part B Cohort 2 enrolment requiring 2 x (3 day treatment period + 7 day washout period). All subjects will complete a follow up visit within seven to 14 days of last dose.
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Being tested
- GSK1325756, Placebo tablet
- Medical subject headings
- Pulmonary Disease, Chronic Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GSK1325756Drug
GSK1325756 will be available as white, film coated immediate release tablets with dose strengths of 50 mg, 100 mg and 200 mg. The tablets will be administered twice daily by oral route with 240 milliliters of water.
Placebo tabletDrug
Placebo will be available as white film coated GSK1325756 matching tablet which will be administered twice daily by oral route with 240 milliliters of water.
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | Part A - Cohort 1 subjects will be administered GSK1325756 matching placebo tablets twice daily following a light meal for one day in accordance with the randomization schedule. Receives: Drug: Placebo tablet |
| GSK1325756 200 mg | Experimental | Part A - Cohort 1 subjects will be administered GSK1325756 200 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule. Receives: Drug: GSK1325756 |
| GSK1325756 50 mg | Experimental | Part A - Cohort 1 subjects will be administered GSK1325756 50 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule. Receives: Drug: GSK1325756 |
| GSK1325756 100 mg | Experimental | Part B - Cohort 2 subjects will be administered GSK1325756 100 mg following a light meal (Fed) or in the fasted state twice daily for one day in accordance with the randomization schedule. Receives: Drug: GSK1325756 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pharmacokinetics
Measured: 48 hours
Secondary outcomes (2)
Pharmacodynamics
Measured: 48 hours
Adverse Events
Measured: 48 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Dec 2010 (estimated)
- Study start5 Nov 2010
- Primary completion27 Jan 2011
- Study completion27 Jan 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Pulmonary Disease, Chronic ObstructiveStudies of the same condition, open and under way.
- More trials run by GlaxoSmithKlineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- GlaxoSmithKline
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- GSK Clinical Trials, Study director, GlaxoSmithKline
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01267006
- Sponsor's protocol ID
- 114922
- Status last verified
- Jul 2017
- First submitted
- 23 Dec 2010
- Last updated
- 7 Jul 2017
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Yes: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Publications
Bloomer JC, Nash M, Webb A, Miller BE, Lazaar AL, Beaumont C, Guiney WJ. Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling. Br J Clin Pharmacol. 2013 Feb;75(2):488-96. doi: 10.1111/j.1365-2125.2012.04352.x.
PubMed 22670830
Study at a glance
From the registry record, last updated by the sponsor on 7 Jul 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Cross-over Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Twice Daily Oral Administration of GSK1325756, Compared to Placebo, in Healthy Subjects; and the Pharmacokinetic Profile of Twice Daily Oral Administration of GSK1325756 in Healthy Fed and Fasted Elderly Subjects
- ClinicalTrials.gov ID
- NCT01267006
- Acronym / sponsor ID
- 114922
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- GlaxoSmithKlineIndustry (pharma, biotech, devices)
- Study start
- 5 Nov 2010 (actual)
- Primary completion
- 27 Jan 2011 (actual)
- Study completion
- 27 Jan 2011 (actual)
- First posted
- 24 Dec 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will invite two groups of volunteers to participate.
The data from one group of volunteers will be used to find out how much study drug, known as GSK1325756, is in the blood after taking the drug twice in one day. Data will also collected to find out if the level of cetain blood cells, known as neutrophils, change significantly after taking the study drug twice in one day. This group of volunteers will be aged 40 to 64 years of age.
The data from the other group of volunteers will be used to find out if taking the study drug, GSK1325756, twice in one day with or without food, makes a difference to the level of study drug in the blood. This group of volunteers will also provide data to find out if any study drug metabolites are present in the bile, a fluid secreted by the liver. This group of volunteers will be aged 65 to 80 years of age.
Detailed description
The current study will be conducted in two parts. In Part A - Cohort 1, healthy fed subjects aged 40 to 64 years (inclusive) will be enrolled to evaluate both the pharmacokinetics and pharmacodynamics of twice daily oral administration of GSK1325756 compared to matching placebo. In Part B - Cohort 2, healthy elderly subjects aged 65 to 80 years (inclusive) will be enrolled to evaluate the pharmacokinetic profile of twice daily oral administration of GSK1325756 for administered under fed and fasted conditions. Parts A and B may be performed in parallel.
The approximate duration of the current study is expected to be between 64 and 74 days. The study will require subjects to complete a screening visit within 30 days, followed by Part A - Cohort 1 enrolment requiring 3 x (3 day treatment period + 7 day washout period) or Part B Cohort 2 enrolment requiring 2 x (3 day treatment period + 7 day washout period). All subjects will complete a follow up visit within seven to 14 days of last dose.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Drug: Placebo tabletPart A - Cohort 1 subjects will be administered GSK1325756 matching placebo tablets twice daily following a light meal for one day in accordance with the randomization schedule. |
| GSK1325756 200 mg | Experimental | Drug: GSK1325756Part A - Cohort 1 subjects will be administered GSK1325756 200 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule. |
| GSK1325756 50 mg | Experimental | Drug: GSK1325756Part A - Cohort 1 subjects will be administered GSK1325756 50 mg immediate release tablets twice daily following a light meal for one day in accordance with the randomization schedule. |
| GSK1325756 100 mg | Experimental | Drug: GSK1325756Part B - Cohort 2 subjects will be administered GSK1325756 100 mg following a light meal (Fed) or in the fasted state twice daily for one day in accordance with the randomization schedule. |
Who may qualify
- Ages
- 40 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Male or non-childbearing potential female who, at the at the time of signing the informed consent, aged between 40 and 64 years (inclusive) for enrolment in Part A - Cohort 1; between 65 and 80 years (inclusive) for enrolment in Part B - Cohort 2. A female of non-childbearing potential is defined as a pre-menopausal female with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea [in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<147 pmol/L) is confirmatory].
- Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures and objectives.
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase and bilirubin less than or equal to 1.5x Upper Limit of Normal (ULN) (isolated bilirubin greater than 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin less than 35%).
- Resting blood pressure (BP) of less than or equal to 140/90, irrespective of anti-hypertensive medication status for the subject.
- Body weight greater or equal to 60 kg for men and greater or equal to 45 kg for women; and Body Mass Index (BMI) within the range 19 to 32 kilograms per metres squared (kg/m2) (inclusive).
Key exclusion criteria (21 listed)
- Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- A neutrophil count at screening of less than 2 x 10*9L. Repeat testing is not permitted.
- A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- A positive pre-study drug/alcohol screen, with the exception of a positive result considered by the investigator to be directly attributable to prescription medication approved for subject use during the study.
- A positive test for HIV antibody.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GSK1325756GSK1325756 will be available as white, film coated immediate release tablets with dose strengths of 50 mg, 100 mg and 200 mg. The tablets will be administered twice daily by oral route with 240 milliliters of water. | Drug | GSK1325756 100 mg, GSK1325756 200 mg, GSK1325756 50 mg |
| Placebo tabletPlacebo will be available as white film coated GSK1325756 matching tablet which will be administered twice daily by oral route with 240 milliliters of water. | Drug | Placebo |
Primary outcome
Pharmacokinetics
Time frame: 48 hours
2 secondary outcomes
Pharmacodynamics
Time frame: 48 hours
Adverse Events
Time frame: 48 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Jul 2017.
- Background: PubMed 22670830Bloomer JC, Nash M, Webb A, Miller BE, Lazaar AL, Beaumont C, Guiney WJ. Assessment of potential drug interactions by characterization of human drug metabolism pathways using non-invasive bile sampling. Br J Clin Pharmacol. 2013 Feb;75(2):488-96. doi: 10.1111/j.1365-2125.2012.04352.x.
- Results for study 114922 can be found on the GSK Clinical Study Register.Link provided by the sponsor.
- Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.Link provided by the sponsor.
- Individual participant dataSharing planned: Yes. Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Related trials for Pulmonary Disease, Chronic Obstructive
Active, not recruiting
Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS
COPD, Smoking
Not yet recruitingPhase 2/3
An Open-Label Extension Study to Evaluate Inhaled Treprostinil SMI in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
Study of Treprostinil Administered Via Soft Mist Inhaler (SMI) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD)
Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease
RecruitingPhase 3
A Study to Investigate the Efficacy and Safety of Belumosudil Compared With Best Available Therapy in Participants Aged 12 Years or Older With Chronic Graft-versus-host Disease
Chronic Graft Versus Host Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
GSK Clinical Trials study director
GlaxoSmithKline
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing GSK1325756 in people with Pulmonary Disease, Chronic Obstructive, run by GlaxoSmithKline at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 21 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Jul 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pharmacokinetics (time frame: 48 hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01267006, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Jul 2017; AzTrials last refreshed its copy on 8 Nov 2026.